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Abstract 
 
We assessed the cost-effectiveness of vaccinating pregnant women against seasonal influenza 
in England and Wales, taking into account the timing of vaccination relative to both the 
influenza season and trimester of pregnancy. Women were assumed to be vaccinated in their 
second or third trimester. Vaccination between September and December was found to have 
an incremental cost-effectiveness ratio of £23,000 per QALY (95% CI £10,000 - £140,000) if 
it is assumed that infants are partially protected through their mothers, and of £29,000 per 
QALY gained (95% CI £14,000 - £200,000) if infants are not protected. If some vaccine 
protection lasts for a second season, then the ratio is only £15,000 per QALY gained (95% CI 
£6,000 - £91,000). Most of the benefit of vaccination is in preventing symptomatic episodes, 
regardless of health care resource use. Extending vaccination beyond December is unlikely to 
be cost-effective unless there is good protection into a second influenza season. Key sources 
of uncertainty are the cost of vaccine delivery and the quality of life detriment due to a 
clinically apparent episode of confirmed influenza. The cost of vaccine purchase itself is 
relatively low. 
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1. Introduction 
 
Vaccination against influenza is currently recommended in the United Kingdom (UK) for 
patients at high risk of influenza-related morbidity and mortality. These patients include 
adults over 65 years old and individuals in clinical risk groups such as those with asthma and 
diabetes, as well as chronic heart, kidney and lung disease [1]. However, healthy pregnant 
women are not included in these risk groups. In contrast, both the United States and Canada 
recommend vaccinating healthy women who will be pregnant during the influenza season 
[2;3] while Australia recommends vaccination of pregnant women in their second or third 
trimester during the influenza season [4]. Pregnancy was also listed as one of the risk 
categories for priority immunisation in the United Kingdom during the 2009 H1N1v swine 
influenza pandemic. The rationale for vaccinating pregnant women is that they have a higher 
risk of complications from influenza which increases with stage of gestation [5;6]. 
 
The Joint Committee on Vaccination and Immunisation (JCVI), after reviewing these severity 
data, advised in 2006 that influenza vaccination should be offered to women in their second 
and third trimester of pregnancy [7]. First trimester women were excluded as the risk-benefit 
profile was not considered favourable [6]. However, as with other health interventions, 
implementation of such advice is subject to favourable cost-effectiveness analysis. It is 
important that any cost-effectiveness analysis takes into account the timing of vaccination, 
specifically the stage of pregnancy at which women become eligible for vaccination and the 
extent to which this overlaps with the influenza season. Also, unlike currently vaccinated risk 
groups, pregnant women will be not be eligible for vaccination each year, (unless a 
subsequent pregnancy also coincidences with the influenza season). Hence, vaccine 
protection in the following season may be an additional benefit that is not accrued for those 
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vaccinated each season.  A further benefit of vaccinating pregnant women  is that their infants 
may benefit through passive immunity [8;9]. 
  
Although two cost-effectiveness analyses of pregnant women in the United States have been 
published [10;11], there are no published cost-effectiveness analyses for the UK (or indeed 
any other part of the world besides the United States). Hence we present the first cost-
effectiveness analysis of seasonal influenza vaccination for pregnant women in the UK, 
which will inform policy making in the UK and be useful for making similar decisions in 
other developed countries. We also consider issues around timing of vaccination and length 
of protection not incorporated into previous analyses. 
 
2. Methods 
 
2.1. Decision analytic model 
 
A decision tree model was used to compare outcomes from cohorts of vaccinated and 
unvaccinated pregnant women, as well as their infants. Women in the model are divided into 
cohorts based on week of pregnancy for the purpose of vaccination, and vaccinated between 
the months of September to December as long as they are in the second or third trimester of 
pregnancy. Vaccine protection is assumed to occur two weeks after vaccination to account for 
the time taken for protective antibodies to rise to sufficient levels [12]. Once vaccinated, they 
are assumed to be protected both during their pregnancy and after, until the next influenza 
season starting the following September. In some scenarios, protection at a lower level is 
assumed to continue in the following season. All analyses were conducted in R (R 
Development Core Team, 2010, http://www.R-project.org). 
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Women have a risk of acquiring a symptomatic influenza infection, which varies according to 
the week of the year and their vaccination status. Each infected woman then has a probability 
of consulting a general practitioner (GP), being hospitalised in a general ward, being admitted 
to intensive care for influenza-related illness or dying of influenza-related causes (Figure 1). 
GP clinic attendees have a probability of being prescribed medication. Infants of mothers 
have a risk of acquiring influenza and of requiring health care or dying as a result. The cost to 
the health service and number of quality adjusted life years (QALYs) gained in vaccinated 
and unvaccinated women (and their infants) are then compared to estimate the incremental 
cost-effectiveness of vaccination. Costs are presented in 2008 £. A time horizon of two years 
post-vaccination is adopted, with costs and benefits incurred at least 12 months post-
vaccination discounted at a rate of 3.5% per annum. A health service perspective is adopted 
(hence excluding productivity changes) and results are present as incremental costs per 
QALYs gained, and the cost-effectiveness of vaccination is evaluated according to the 
threshold of £20,000 - £30,000 per QALY gained, as recommended by the National Institute 
for Health and Clinical Excellence [13]. 
  
2.2. Data sources 
 
Population. The average number of maternities in England and Wales in the years 2002-2007 
(the years for which these data are available) is 637,585 [14]. These are assumed to be 
uniformly distributed throughout the year. However, about 10% of the population aged 15-44 
years is in a clinical risk group [15], and so would already be eligible to receive vaccination. 
It is therefore assumed that vaccination would be offered to an additional population of 
570,000 pregnant women each year.  
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Hospitalisations. Most influenza-related hospital admissions are not recorded using an 
influenza code. The true number of hospitalisations due to influenza was estimated using a 
regression technique previously used for estimating the burden of rotavirus disease [16] and 
influenza [17]. Full details of the analysis are given in Supplement S1. Briefly, hospital 
admissions in 2000 – 2009 for respiratory illness with infectious causes in pregnant women 
not in clinical risk groups were extracted from Hospital Episode Statistics (HES). In addition, 
weekly counts of respiratory pathogens in 2000 – 2009 for the 15-44 year old age group were 
extracted from LabBase2, a surveillance database that records the number of laboratory 
confirmed samples of various pathogens reported to the Health Protection Agency [18]. The 
seasonal pattern of laboratory reports was then used to estimate the proportions of 
hospitalisations in each week of the year that due to various pathogens. An equivalent 
analysis was performed on infants aged 0-5 months, the age group deemed to be potentially 
partially protected by maternal antibodies and hence by vaccinating mothers. The risk of 
hospitalisation for influenza in infants under one month old is very low as most 
hospitalisations were attributable to other organisms particularly respiratory syncytial virus; 
hence we removed this group from the analysis. 
 
Intensive care. Comprehensive data on intensive care admissions are not available on the 
HES database [19]. Hence the risk of a pregnant woman already hospitalised for influenza 
being admitted to intensive care was estimated from two sources: (i) the placebo arms of 
published trials of influenza-related interventions [20-23] (assuming that the risk is no 
different for pregnant women) and (ii) data on intensive care admissions gathered during the 
2009 H1N1 pandemic (assuming that the risk is no different for seasonal influenza). The 
reported risks lie between 2.8% and 17.9% (details in the Supplement S2). 
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GP consultations. The incidence of GP consultations for lower respiratory tract infections in 
females aged 15-44 years old from 2001 to 2008 was extracted from the Royal College of 
General Practitioners (RCGP) Weekly Returns Service [24], an anonymised database with 
information from approximately 70 sentinel practices in England and Wales. These included 
consultations with a READ code for pleurisy, pneumonia, bronchitis, laryngitis and 
influenza-like illness (ILI). Two methods were used to estimate the proportion of these 
consultations attributable to influenza: (i) multiple linear regression with laboratory reports of 
respiratory pathogens to estimate the proportion of all lower respiratory tract infections due to 
influenza (as with hospitalisations), and (ii) using consultations for ILI on their own. The 
second method assumes that consultations for ILI that are not for influenza are offset by 
consultations due to influenza not recorded as ILI. The annual risk of having a GP 
consultation for influenza in this population was estimated to be 1.9% and 2.4% using the 
first and second method respectively, and 2.2% when both estimates were combined (details 
in Supplement S3). This is significantly higher than an earlier estimate of 0.72% for the 
incidence of GP consultations in the population of England and Wales using data from the 
General Practice Research Database (GPRD) [17], possibly because not all consultations are 
coded in the GPRD [25]. 
 
The RCGP data do not provide information on pregnancy status, so the increased risk of an 
influenza-related GP consultation in each trimester of pregnancy compared to non-pregnant 
women in the same age group was estimated using data from the GPRD instead. The GPRD 
contains medical records for about 2000 representative general practitioners in the United 
Kingdom [26]. All consultations for ILI occurring between 1 January 1992 and 30 June 2007 
for individuals aged 15-44 years with at least 2 years of continuous follow up were extracted. 
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For each individual, ILI episodes were regarded as separate if they occurred more than 28 
days apart. A total of 35,706 records of ILI for analysis in 29,606 women were extracted 
from the GPRD database. For these women, READ codes indicating a delivery were used to 
determine whether a birth occurred, and if so, its date. The relative incidence of ILI at 
different stages of pregnancy was then estimated using the self controlled case-series method, 
which automatically adjusts for individual level confounding [27].  
 
Medication. A population-based study using consultations for influenza-like illness in the 
GPRD found that 45.3% of patients aged 15-64 years old were prescribed antibiotics, and 
17.7% were prescribed antipyretics or analgesics [28]. Other categories of drugs were rarely 
prescribed. It is likely that antibiotic prescribing rates have decreased since the study was 
conducted (1991-1996). As a rough estimate, it was assumed that the total number of 
prescriptions for drugs for influenza was 50% of the number of GP visits for influenza. 
 
Deaths. The HES database recorded 28 deaths between 2001 and 2008 in pregnant women 
hospitalised for respiratory disease with no underlying health condition. Multiplying the 
deaths in each month by the proportion of respiratory hospitalisations attributed to influenza 
in that period gives an estimated 0.97 deaths due to influenza in pregnancy per year, with a 
risk of dying of 0.0029% per case. The risk of death in non-pregnant adult women was 
adjusted using the reduction in the risk of hospitalisation after pregnancy. The coefficient of 
variation for influenza deaths was assumed to be the same as that for hospitalisation. The 
average age of pregnancy was assumed to be 29 years [29], with the quality-adjusted life 
years lost due to influenza calculated using mortality rates by age group and health-related 
quality of life scores from the general population [30]. Hence we estimated that the death of 
an infant and a pregnant mother result in 20.0 and 23.8 QALYs lost respectively. The risk of 
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death in infants was taken from the estimated annual number of deaths due to influenza A and 
B from a regression analysis on respiratory disease data from the Office for National 
Statistics [17]. 
 
Attack rate for confirmed clinically apparent influenza. The incidence of confirmed influenza 
accompanied by clinical symptoms in adults was estimated using data from the placebo arms 
of clinical trials of influenza prophylaxis (vaccines or antiviral drugs). Since there were no 
data for pregnant women, it was assumed that healthy pregnant women had the same risk of 
clinical influenza as other healthy adults. Five studies [31-35] were identified as being 
relevant as they were published after 1990, actively followed a cohort of healthy adults for 
clinical respiratory symptoms and incorporated laboratory confirmation of influenza infection 
(see Table 1). All five were based in the United States. The attack rates in placebo recipients 
from the five studies based were then combined using a random effects model to give a 
pooled estimate of 5.9%. Weekly counts for influenza A and B isolates extracted from the 
LabBase2 database were used to determine the seasonality of these episodes of influenza. For 
infants, because of lack of data, we conservatively estimated that all symptomatic influenza 
episodes are captured by the incidence of hospitalisations. 
 
Vaccine characteristics. A recent Cochrane review pooled results from several randomised 
studies of seasonal influenza vaccine efficacy using a random effects model. Efficacy was 
reported as 80% (95% CI 56% – 91%) against strains that matched the circulating strain [36]. 
Data are lacking on vaccine efficacy in pregnant women, so it was assumed that the vaccines 
equally efficacious in this population. Vaccination with a poorly matched strain [36;37] or a 
previous year’s strain  [38;39] has lower efficacy compared to vaccinating with a well-
matched current strain of influenza. Additionally, immunogenicity against clinical endpoints 
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following vaccination has been found to wane over a period of months, even within the same 
influenza season [40;41].  Hence in scenarios where vaccine protection lasted a second 
season, vaccine efficacy was assumed to be half of that in the first season (i.e. 40%). 
 
Two studies suggest that vaccinating mothers would protect their infants. A randomised study 
in Bangladesh found a 63% (95% CI 5 – 85) reduction in laboratory-confirmed influenza in 
infants under 24 weeks old whose mothers had received influenza vaccines, compared to a 
control group whose mothers received a pneumococcal vaccine [8]. A case-control study in a 
Connecticut hospital found a 79% (95% CI 25 – 94) reduction in infants under 6 months old 
[9]. We combined both results with equal weight to estimate the protective effect of 
vaccinating mothers on their children under six months old. 
 
Vaccination coverage was assumed to be 45%, approximately based on reported coverage of 
the seasonal influenza vaccination among high risk individuals under 65 in 2007/8 [42]. 
 
Quality of life detriment due to influenza. An analysis of patient-reported health state 
valuations in placebo-controlled trials of oseltamivir reported that 4.27 (95% CI 1.28 – 7.04) 
quality adjusted life days were lost per episode of symptomatic influenza [43], corresponding 
to a QALY loss of 0.0117 (95% CI 0.0035 – 0.019). During the 2009 influenza pandemic, a 
questionnaire-based study among individuals with confirmed influenza resulted in an 
estimate of 0.0082 (95% CI 0.0066 – 0.0098) QALYs lost per influenza episode [15]. 
Combining both estimates with equal weight gives an overall QALY loss per episode of 
0.010 (95% CI 0.0012 – 0.019). 
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For hospital and ICU admissions, quality of life weights of 0.65 and 0.52 respectively were 
used, based on an expert consultation convened by the Institute of Medicine [44]. Given the 
lack of information about uncertainty around these estimates, they were varied over 
symmetrical triangular distributions up to a maximum quality of life weight of 0.87 (the 
average quality of life for someone aged 20-39 years old [30]. The estimated length of stay 
for influenza hospitalisations was 3.68 days (95% CI 2.91 - 4.45), using admissions for 
influenza-like respiratory illnesses in HES regressed against respiratory pathogens in 
LabBase2 (see Supplement S1). The quality of life weights were multiplied by the average 
length of hospital stay for influenza to obtain the additional quality of life detriment incurred 
by patients admitted to acute care, on top of the usual detriment for symptomatic influenza.  
 
Adverse events following vaccination. There is no evidence that influenza immunisation is 
associated with any serious adverse events in pregnant women or their children [5], although 
immunisation is associated with a raised risk of mild adverse events in adults [36]. It was 
assumed that these events had no significant quality of life implications. In a previous cost-
effectiveness analysis [43], systemic adverse reactions to vaccination were assumed to occur 
in about 1% of vaccinated individuals and be equivalent to having influenza for a single day. 
However, this may be an overestimate, since reported adverse events following vaccination 
are typically far milder than actual influenza [6]. 
 
Health care costs. NHS reference costs for a non-elective admission for unspecified acute 
lower respiratory infection with complications and comorbidities (code DZ22B) were used to 
estimate the cost of a hospital episode for influenza in a pregnant woman. For intensive care 
admissions, the cost of an episode of adult critical care with one organ supported (code 
XC06Z) was used. The cost of an intensive care admission is in addition to the cost of the 
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hospitalisation that resulted in the time in intensive care. A GP consultation was costed on the 
basis of a clinic consultation of 17.2 minutes, including qualification and direct care staff 
costs [45]. The cost of prescriptions for influenza was based on the price to the health service 
of three drugs commonly prescribed for influenza-like illness in pregnant women (penicillin, 
erythromycin and paracetamol) [46]. 
 
The British National Formulary holds details on twelve seasonal influenza vaccines indicated 
for use in the United Kingdom. The cost per dose of the vaccines ranges from £4.40 to £9.05 
with an average of £6.04 [46]. In addition, a 10% vaccine wastage rate was assumed. Vaccine 
administration costs of £7.51 per person vaccinated were assumed based on the item of 
service payment to GPs for vaccination. This was varied between £5.50 (ten minutes of client 
contact time for a band 5 practice nurse) to £10.33 (ten minutes for a midwife, i.e. a band 7 
advanced nurse). 
 
2.3. Sensitivity analysis 
 
The influence of all epidemiological and economic parameters on the incremental cost-
effectiveness ratio was jointly explored using probabilistic sensitivity analysis. Monte Carlo 
sampling was conducted on the joint distribution of the parameters (see Table 2), with 50,000 
samples drawn. The relative influence of each parameter on the cost-effectiveness of 
vaccination was explored using a multivariate linear regression model, with parameter values 
as predictors and the incremental cost-effectiveness ratio as outcome. To correct for 
heteroskedasticity and reduce the influence of non-linearities at extreme values, robust 
standard errors were used and the most extreme 5% of outcomes were excluded. The 
regression coefficient for each parameter was multiplied by the endpoints of the parameter’s 
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corresponding 95% credibility interval to obtain a predicted range for the incremental cost-
effectiveness ratio when the parameter is varied. In addition, univariate sensitivity analysis 
was conducted on two key parameters (attack rate and QALY loss associated with clinically 
apparent influenza). Lastly, two scenarios about the efficacy of vaccination in the second 
season (i.e. beyond the September following vaccination) were explored; one in which the 
vaccine continued to provide full protection and another in which the vaccine no longer 
protected. 
 
2.4. Optimal period for vaccination 
 
The optimal period in the year in which to administer seasonal influenza vaccination to 
pregnant women was explored.  It was assumed that the new season’s vaccines would be 
available from September, and that women are vaccinated only during their second or third 
trimester of pregnancy. The cheapest option (apart from no vaccination) would be to 
vaccinate all women in their second or third trimester in September. The incremental cost-
effectiveness of the second cheapest option, vaccinating all women in their second or third 
trimester in September and October, was compared to a September-only option, and so on. 
 
3. Results 
 
The incremental cost-effectiveness ratio is £23,000 per QALY gained (95% CI £10,000 - 
£140,000) under base case assumptions (infants partially protected through their mothers, and 
no efficacy after the first season). If infants are not protected, this rises to £28,000 per QALY 
gained (95% CI £13,000 - £200,000). However, if mothers and infants are protected for a 
second season, this drops to only £15,000 per QALY gained (95% CI £6,000 - £93,000). 
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A total of 200,000 women are expected to be vaccinated each season. Under base case 
assumptions, vaccination is expected to prevent 3,200 (2,100 – 4,100) GP consultations, 290 
(180 – 420) hospitalisations, 18 (8 – 30) ICU admissions and 0.33 (0.24 – 0.42) deaths in that 
vaccinated cohort. A total of 9,000 (6,600 – 10,000) episodes of influenza are estimated to be 
prevented and 96 (16 - 180) QALYs saved. The cost of the programme is estimated to be 
£2.2 million (£1.4 - £3.0 million), but reduce expenditure on primary and acute care by 
£590,000 (£280,000 - £1.1 million). 
 
Figure 2 shows corresponding cost effectiveness acceptability curves. With a threshold of 
£30,000 per QALY gained, 69%, 54% and 87% of Monte Carlo samples are considered cost-
effective for the base case scenario, scenario without infant protection and scenario with 
second season protection respectively. With a more stringent threshold of £20,000 per QALY 
gained, the corresponding proportions are 38%, 20% and 70%. This indicates that vaccination 
could be regarded as borderline cost-effective without second season protection, and very 
cost-effective with such protection, based on the criteria used by the National Institute for 
Health and Clinical Excellence. 
 
The most influential parameters affecting the incremental cost-effectiveness ratio are shown 
as a tornado plot in Figure 3. Figure 4 shows how the incremental cost-effectiveness ratio 
changes when two key parameters (QALY loss due to clinically apparent influenza and 
administrative cost of the vaccine) are varied. Assuming infant protection and no protection 
beyond the first season, a QALY loss of about 0.007 per episode of influenza (instead of 
0.01) is enough to push the incremental cost-effectiveness of vaccination above £30,000 per 
QALY gained. Similarly, a vaccine administration cost of about £11 per dose (instead of 
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£7.51) will make vaccination cease to be cost-effective at a threshold of £30,000 per QALY 
gained. 
 
Figure 5 shows the incremental cost-effectiveness vaccination of extending a vaccination 
programme starting in September, to different months of the year. With a willingness to pay 
threshold of £30,000 per QALY gained, vaccination should be carried out between 
September and December. However, if vaccine protection lasts beyond a first season then 
vaccination would be cost-effective under that threshold up to May. 
 
4. Discussion 
 
Vaccinating pregnant women against seasonal influenza may be cost-effective, with an 
incremental cost-effectiveness ratio of around £23,000, assuming protection for a single 
season and some benefit to infants. 
 
This analysis uses a regression-based technique to determine the proportion of health care 
attendances that may be attributable to influenza. Recently, the assumptions used by such 
ecological models have been questioned by Gilca and co-workers [47]. The method we have 
used here takes into account many of the issues they raise, which have been ignored by some 
previous models, including differential rates of disease reporting by organism, variation of 
circulating organisms by age group and secular trends in disease incidence (such as the 
occurrence of epidemic seasons at different times each year). While we have not considered 
changes in reporting rates over time, when there is indication of a long-term variation in 
reporting rates (such as for GP consultations for LRTI), we have used several models 
including ones which incorporate a term for year of reporting. All the models give broadly 
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similar conclusions for the proportion of consultations attributable to influenza, so we have 
achieved some degree of internal validation and thus have some confidence in the robustness 
of our results. 
 
Our findings appear less optimistic than those in the study of maternal influenza 
immunisation in the United States [10], which estimated that vaccination would be cost-
effective from a third party payer perspective as long as the overall attack rate was over 2.5% 
(compared to 5.9% used in our model). However, the American model did not consider the 
timing of vaccination and seasonality of influenza, and hence the possibility that a woman 
would not be vaccinated in time to be protected throughout the influenza season. 
 
The favourable cost-effectiveness of vaccination depends on several assumptions. The cost of 
delivering vaccination is important because the actual cost of purchasing the vaccine is 
comparatively low. The base case administration cost is based on the item of service payment 
to GPs; however, this is an internal transfer cost which does not take into account the cost of 
actual clinician time. Hence the way the vaccine is delivered is crucial. Our model suggests 
that vaccination will need to be delivered largely by practice nurses during routine antenatal 
appointments to be clearly cost-effective. If midwives deliver vaccines, then vaccination may 
be marginally cost-effective. If a separate appointment for vaccination needs to be made, or if 
vaccination is delivered by GPs themselves (for whom ten minutes of client contact time is 
estimated to cost £30.50), then vaccination is highly unlikely to be cost-effective regardless 
of other assumptions made. 
 
Another key assumption is the estimate of the QALY loss due to influenza, which was 
obtained from a study that combined health state valuations on a disease-specific Likert scale 
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from the placebo arm of four clinical trials of oseltamivir, and transformed the outcomes into 
quality of life weights [43]. There is substantial uncertainty around the resulting estimate, 
both due to variability in the results from primary data sources (reflected in the large 
confidence intervals around the distribution of possible QALY loss values), as well as 
uncertainty about the validity of the mapping process. The second estimate is from direct 
measurements of patients with laboratory confirmed influenza using the EuroQol EQ-5D 
instrument. However, the study was conducted during the 2009 influenza pandemic so its 
validity outside a pandemic situation is not established. This highlights the need for a study to 
obtain valuations from patients with seasonal influenza using the EQ-5D. A further issue is 
that the health state valuations were done in the general adult population rather than in 
pregnant women. It is not known whether pregnancy may induce a different quality of life 
detriment as a result of influenza (apart from the greater risk of GP consultations and 
hospitalisations in pregnant women with influenza). However, a comparison of symptoms in 
pregnant and non-pregnant individuals of reproductive age with H1N1v influenza found no 
significant differences in symptoms apart from shortness of breath [48]. Furthermore, any 
differential in the quality of life detriment is more likely to indicate that pregnancy worsens 
the impact of influenza rather than ameliorating it, hence making vaccination more cost-
effective. 
 
Vaccinating pregnant women is likely to be more cost-effective than vaccinating the wider 
adult population for several reasons. Firstly, pregnant women are at a higher risk of 
influenza-related GP consultations and hospitalisations compared to non-pregnant women of 
the same age [5]. Nevertheless, such cases still contribute to only a very small proportion of 
all clinically apparent influenza cases, since the incidence of influenza patients using health 
care resources (GPs, hospitals and intensive care units) is low compared to the overall burden 
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of clinically apparent influenza. We estimate that pregnant women with influenza have only a 
14% risk of influenza-related GP consultation and 2.2% risk of influenza-related 
hospitalisation. Consequently, the increased cost-effectiveness of vaccinating pregnant 
women compared to other healthy adults is mainly due to potential vaccine protection for 
infants of vaccinated mothers, and potential persistence of vaccine protection beyond the first 
influenza season (which is not relevant to other seasonal vaccination programmes since 
individuals are revaccinated every influenza season). If these benefits are not included, then 
the cost effectiveness of vaccinating pregnant women is expected to be only slightly better 
than that of vaccinating the entire healthy adult population. However, it is not clear whether 
and how the incidence of seasonal influenza will change after the H1N1 pandemic of 2009 
which has the potential to displace strains of influenza that were predominant prior to the 
pandemic. Such changes are likely to affect the cost-effectiveness of vaccinating both 
pregnant women and the wider adult population. Also, if there is a means of prolonging the 
efficacy of the vaccines (perhaps by using adjuvanted vaccines) then vaccinating pregnant 
women would become more cost-effective. 
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Caption for supplemental material (submitted in a separate file) 
 
Technical details of calculations used to estimate the burden of disease due to influenza in 
pregnant women. 
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Table 1. Attack rate of confirmed influenza with clinical symptoms reported from the 
placebo arm of five influenza prophylaxis trials in healthy adults. 
 
First 
author 
Intervention Case definition Attack rate 
(placebo arm) 
Sample 
size 
Bridges 
[31] 
Influenza 
vaccination 
Clinical symptoms and culture 
confirmation 
7.3% 274 
Monto 
[32] 
Antivirals Clinical symptoms and culture 
confirmation 
6.1% 554 
Hayden 
[33] 
Antivirals Clinical symptoms and culture 
confirmation 
4.8% 519 
Wilde 
[34] 
Influenza 
vaccination 
Clinical symptoms and 
serological confirmation 
7.0% 358 
Powers 
[35] 
Influenza 
vaccination 
Clinical symptoms and 
serological confirmation or viral 
isolation 
12.5% 24 
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Table 2. Distributions used for the parameters in the model. 
 
Parameter Mean Distribution Source 
Epidemiological parameters 
Probability that a 
pregnant woman is 
hospitalised with 
influenza in the 
  
 
 
Normal with  
Hospital Episode 
Statistics, laboratory 
reports (see 
Supplement S1) 
... first trimester 0.089% =0.089%, =0.0091%  
… second trimester 0.11% =0.11%, =0.011%  
… third trimester 0.20% =0.20%, =0.020%  
Probability that any 
adult woman is 
hospitalised with 
influenza 
0.0051% Normal with  = 
0.0051%,  = 0.0014% 
[17] (see Supplement 
S1) 
Probability that any 
infant aged 1-6 months 
is hospitalised with 
influenza 
1.25% Normal with  = 
1.25%,  = 0.22% 
HES, LabBase2 (see 
Supplement S1) 
Probability that 
someone hospitalised 
for influenza is 
admitted to intensive 
care 
10% Triangular with 
min=3%, max=17%, 
mode=10% 
[20-23]; data on file 
from the 2009 
influenza H1N1 
pandemic (see 
Supplement S2) 
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Probability that any 
pregnant woman 
consults a GP with 
influenza in the 
  
 
 
Normal with 
RCGP Weekly Returns 
Service [24], GPRD 
[26] (see Supplement 
S3) 
… first trimester 2.46% =2.46%, =0.35%  
… second trimester 2.70% =2.70%, =0.45%  
… third trimester 2.33% =2.33%, =0.39%  
Probability that any 
adult woman consults a 
GP with influenza 
2.2% Normal with  = 2.2%, 
 = 0.35% 
RCGP Weekly Returns 
Service [24], GPRD 
[26] (see Supplement 
S3) 
Probability that GP 
consultation for a 
pregnant woman with 
influenza results in a 
prescription 
50% Triangular with 
min=37%, max=63%, 
mode=50%  
[28] 
Probability of death for 
a pregnant woman with 
influenza 
0.0029% Normal with  = 
0.0029%,  = 
0.00029% 
[19] 
Probability that any 
infant dies of influenza 
0.00074% Normal  = 0.00074%, 
 = 0.00017% 
[17] 
Attack rate (incidence 
of confirmed clinically 
apparent influenza) 
5.9% Normal with  = 5.9%, 
 = 0.0060% 
[31-35] (see Table 1) 
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Outcomes 
QALYs lost due to 
influenza episode 
0.010 Normal with  = 
0.010,  = 0.0044 
[43] 
Quality of life 
detriment during 
influenza hospital 
episode 
0.35 Triangular with 
min=0.13, max=0.57, 
mode=0.35 
[30;44] 
Quality of life 
detriment during 
influenza intensive 
care episode 
0.48 Triangular with 
min=0.13, max=0.83, 
mode=0.48 
[30;44] 
Length of hospital stay 
for influenza (days) 
3.68 Normal with  = 
3.68,  = 0.39 
Hospital Episode 
Statistics, laboratory 
reports (see 
Supplement S1) 
 
Costs (in £) 
Hospitalisation 1446 Lognormal with  = 
7.2,  = 0.35 
[49] 
Intensive care 983 Lognormal with  = 
6.8,  = 0.40 
[49] 
GP consultation 52 Lognormal with  = 
3.7,  = 0.68 
[45] 
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GP prescription 1.62 Triangular with 
min=1.18, max=1.89, 
mode=1.78 
[46] 
Dose of vaccine 6.04 Triangular with 
min=4.4, max=9.1, 
mode=4.62 
[46] 
Administration cost 10.33 Triangular with 
min=5.67, max=18, 
mode=7.32 
[50] 
 
Vaccine characteristics 
Vaccine efficacy 80% Lognormal with  = 
80%,  = 56% 
[36] 
Influenza risk 
reduction in children 
aged 1-6 months of 
vaccinated mothers 
71% Triangular with a = 
63%, b = 79%, c = 
71% (mean=71%) 
[8;9] 
Vaccine wastage 10% Fixed Assumed 
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Figure captions 
 
Figure 1. Decision tree for vaccination of a pregnant woman. The probability of each branch 
in the tree depends on the month of conception and the incidence of influenza in a given 
month. Note that a patient may have more than one health care use outcome, although this is 
not shown in the tree. 
 
Figure 2. Cost-effectiveness acceptability curve for the programme of vaccinating pregnant 
women against seasonal influenza, with and without assuming that their infants are also 
partially protected. Shaded bars indicate the region £20,000-£30,000 per QALY gained. 
 
Figure 3. Tornado graph showing the ten most influential parameters on the incremental 
cost-effectiveness ratio. Shaded bars indicate the region £20,000-£30,000 per QALY gained. 
 
Figure 4. Univariable sensitivity analysis on QALY loss for clinically apparent influenza and 
administrative cost of vaccination. Shaded bars indicate the region £20,000-£30,000 per 
QALY gained. 
 
Figure 5. Incremental cost-effectiveness of extending a vaccination programme starting in 
September, to different months of the year, when the vaccine (a) protects for a single season 
and (b) protects partially up to a second season. Infant protection is assumed. 
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Vaccine – Jit – Figure 2
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Vaccine – Jit – Figure 3
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